Trump left with nowhere to turn as latest health bill fails

28 July 2017
protest_healthcare_senate_big

Donald Trump has suffered arguably his biggest setback as US President yet, with a humiliating defeat in his attempts to repeal Obamacare.

Breaking up his predecessor Barack Obama’s signature healthcare policy, offically called the Affordable Care Act (ACA), was a key campaign pledge for Mr Trump, and it looked like it was soon to happen when the House of Representatives voted to repeal and replace it in May, albeit following amendments.

But at that point Reuters warned that Mr Trump’s victory could prove short-lived as the healthcare legislation headed into a likely tough battle in the Senate, and so it has proved, with successive defeats in attempts to quash Obamacare, which the Republicans argue stretches government intervention too far and has driven some insurance premiums up.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical